{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-017546","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.497056+00:00","generated_at":"2026-05-16T01:38:39.201396+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC Therapeutics reports FY2025 product/royalty rev $831M, beats guidance; Sephience Q4 rev $92M","bullets":["Full-year 2025 product/royalty revenue $831M, exceeding guidance; total revenue $1.73B (includes $998M Novartis collaboration).","Sephience launch strong: Q4 rev $92M ($81M US), 946 patients on therapy; full-year rev $111M.","Net income $682.6M for FY2025 vs net loss $363.3M in FY2024; cash $1.95B as of Dec 31.","Sold Evrysdi royalty to Royalty Pharma for $240M upfront + up to $60M milestones; retains $150M Roche milestone.","2026 guidance: product rev $700-800M (19-36% growth); Phase 3 HD trial INVEST-HD to start 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-017546","json":"https://secwatch.observer/filing/0001104659-26-017546.json","markdown":"https://secwatch.observer/filing/0001104659-26-017546.md","text":"https://secwatch.observer/filing/0001104659-26-017546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/0001104659-26-017546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:38:39.201396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}